GSK Settles Direct Buyers' Wellbutrin Claims For $49M
GlaxoSmithKline PLC on Friday agreed to pay $49 million to end class action claims from direct purchasers of Wellbutrin SR accusing the drugmaker of filing baseless patent suits to delay generic...To view the full article, register now.
Already a subscriber? Click here to view full article